DHMP PROVIDER NEWSLETTER

DENVER HEALTH MEDICAL PLAN INC.™

March 18, 2026

FORMULARY UPDATES TO DHMP COMMERCIAL PLANS DHHA: (HMO/POS) AND MEDICAID/CHP PLANS

Denver Health Medical Plan (DHMP) may add or remove drugs from the formulary or make changes to restrictions on formulary drugs during the year. If DHMP removes drugs from the formulary, or adds a restriction to an existing formulary drug, such as prior authorization, quantity limits and/or step therapy, and/or moves a drug to a higher cost-sharing tier, DHMP will notify you of midyear change(s) at least 60 days before the date that the change becomes effective. If the Food and Drug Administration (FDA) deems a drug on the formulary to be unsafe, or the drug's manufacturer removes the drug from the market, DHMP will immediately remove the drug from the formulary.

The table below outlines previous and/or recent changes to the formulary. The newest updates are highlighted in green. For questions or if you would like more information related to these changes, please call the DHMP Pharmacy Services Department at 303-602-2070 or 877-357-0963.

FORMULARY ABBREVIATIONS

(Explanations can be found on the website in the DHMP Commercial Formulary and Pharmaceutical Management Procedures):

LA = Limited Access (must be filled at DH Pharmacy or PA Required)

PA = Prior Authorization

PREV = Preventative Medication

QL = Quantity Limit

ST = Step Therapy

Pharmacy & Therapeutics Updates

Requests for Drug Class Reviews, PA Criteria Updates, or Formulary Additions

Providers may submit requests for drug class reviews, prior authorization (PA) criteria reviews or updates, and formulary change requests by emailing:

ManagedCarePAR@dhha.org

Please include all relevant clinical information to support your request. Requests are not guaranteed but the pharmacy team will review and submit to the P&T committee and/or leadership for final approval.

Dexcom G7 15 Day Sensors – Formulary Update

The Dexcom G7 15 Day continuous glucose monitoring sensors will be added to the formulary effective April 1, 2026.

Requests received before April 1, 2026 will be reviewed under the existing Continuous Glucose Monitor Prior Authorization criteria.

- Providers should ensure clinical documentation aligns with current PA requirements for review prior to the formulary effective date.